BioSig Technologies, Inc.

  • Home
  • About BioSig
    • Overview
    • Leadership
    • Bioelectronic Medicine
    • Partnerships
  • Pure EP
    • Our Solution
    • Publications
    • Physician Insights
  • News & Media
    • Overview
    • Press Releases
    • BioSig in the News
    • Presentations
    • Events
    • CEO Blog
  • Investors
    • Investor Relations
    • Overview
    • News / Events
    • Press Releases
    • IR Calendar
    • Email Alerts
    • Company Info
    • Profile
    • Presentations
    • Management Team
    • Contacts
    • FAQ
    • Financial Info
    • Balance Sheet
    • Income Statement
    • Cash Flow
    • Financial Results
    • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
    • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
    • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Contact
Investors

Investors

  • Overview
  • News / Events
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Profile
    • Presentations
    • Management Team
    • Contacts
    • FAQ
  • Financial Info
    • Balance Sheet
    • Income Statement
    • Cash Flow
    • Financial Results
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Investor Tools
    • Email Alerts
    • Fact Sheet
    • Contacts
    • RSS News Feed

Press Releases

  • News / Events

  • Press Releases
  • IR Calendar
  • Email Alerts

BioSig Issues April 2020 Shareholder Update Letter

April 17, 2020

Mayo Clinic Preparing to Commence Phase II FDA Clinical Trial for the Treatment of COVID-19 with Vicromax™

April 16, 2020

Positive Data Generated by BioSig Subsidiary ViralClear on COVID-19 Coronavirus Published in bioRxiv

April 9, 2020

BioSig to Host Telebriefing on Development Updates Regarding Vicromax(tm), a Novel Broad-Spectrum Anti-Viral Candidate That May Treat COVID-19

April 3, 2020

Jerome Zeldis, M.D., Ph.D, Appointed as Executive Chair of ViralClear Pharmaceuticals, Inc.

March 31, 2020

BioSig subsidiary NeuroClear acquires license for a broad-spectrum anti-viral agent that may treat COVID-19. Laboratory results demonstrate high level of activity against COVID-19 in cell culture

March 25, 2020

Florida Cardiologist Zachariah P. Zachariah, M.D. Joins BioSig Technologies, Inc. Advisory Board

March 10, 2020

BioSig Appoints John W. Osborn, Ph.D. as Consultant on Autonomic Neuromodulation

March 4, 2020

BioSig to Webcast its Presentation at the Cowen and Company’s 40th Annual Health Care Conference

March 3, 2020

BioSig to Present at the Cowen & Co. 40th Annual Health Care

February 26, 2020
RSS
    • 1...
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • 11
    • ...24
    Award
    BioSig Technologies, Inc.
    Sign Up for BioSig Updates Contact Us
    Twitter linkedin Facebook
    © 2021 BioSig Technologies, Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap